151 related articles for article (PubMed ID: 32175090)
1. A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption.
Peluso MJ; Dee L; Campbell D; Taylor J; Hoh R; Rutishauser RL; Sauceda J; Deeks SG; Dubé K
J Virus Erad; 2020 Feb; 6(1):34-37. PubMed ID: 32175090
[TBL] [Abstract][Full Text] [Related]
2. "It comes altogether as one:" perceptions of analytical treatment interruptions and partner protections among racial, ethnic, sex and gender diverse HIV serodifferent couples in the United States.
Campbell DM; Dubé K; Cowlings PD; Dionicio P; Tam RM; Agarwal H; Stockman JK; Auerbach JD; Sauceda JA; Conroy AA; Johnson MO
BMC Public Health; 2022 Jul; 22(1):1317. PubMed ID: 35810288
[TBL] [Abstract][Full Text] [Related]
3. Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research.
Dubé K; Kanazawa J; Dee L; Taylor J; Campbell DM; Brown B; Johnson MO; Saberi P; Sauceda JA; Sugarman J; Peluso MJ
HIV Res Clin Pract; 2021 Feb; 22(1):14-30. PubMed ID: 33757411
[No Abstract] [Full Text] [Related]
4. HIV remission trial investigators' attitudes towards risk and risk mitigation in trials that include treatment interruption.
Okumu EA; Henderson GE; Golin C; Kuczynski K; Ormsby NQ; Peay HL
J Virus Erad; 2023 Jun; 9(2):100331. PubMed ID: 37416088
[TBL] [Abstract][Full Text] [Related]
5. Understanding participant perspectives around HIV-1 cure-related studies involving antiretroviral analytical treatment interruptions in the United Kingdom.
Lee MJ; Godakandaarachchi P; Collins S; Racz M; Sharp A; Fidler S; Fox J
J Virus Erad; 2023 Dec; 9(4):100360. PubMed ID: 38188642
[TBL] [Abstract][Full Text] [Related]
6. A partner protection package for HIV cure-related trials involving analytical treatment interruptions.
Dubé K; Morton T; Fox L; Dee L; Palm D; Villa TJ; Freshwater W; Taylor J; Graham G; Carter WB; Sauceda JA; Peluso MJ; Rid A
Lancet Infect Dis; 2023 Oct; 23(10):e418-e430. PubMed ID: 37295453
[TBL] [Abstract][Full Text] [Related]
7. Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies.
Lau JSY; Smith MZ; Allan B; Martinez C; Power J; Lewin SR; McMahon JH
AIDS Res Hum Retroviruses; 2020 Apr; 36(4):260-267. PubMed ID: 31608648
[TBL] [Abstract][Full Text] [Related]
8. Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States.
Bilger A; Plenn E; Barg FK; Rendle KA; Carter WB; Lamour-Harrington A; Jones N; Peterson B; Sauceda JA; Tebas P; Mounzer K; Metzger D; Montaner LJ; Dubé K
HIV Res Clin Pract; 2023 Oct; 24(1):2267825. PubMed ID: 37837376
[TBL] [Abstract][Full Text] [Related]
9. Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry.
Dubé K; Kanazawa J; Campbell C; Boone CA; Maragh-Bass AC; Campbell DM; Agosto-Rosario M; Stockman JK; Diallo DD; Poteat T; Johnson M; Saberi P; Sauceda JA
AIDS Res Hum Retroviruses; 2022 Jan; 38(1):50-63. PubMed ID: 33947268
[TBL] [Abstract][Full Text] [Related]
10. Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States.
Dubé K; Ndukwe SO; Korolkova A; Dee L; Sugarman J; Sauceda JA
HIV Res Clin Pract; 2024 Jan; 25(1):2312318. PubMed ID: 38348830
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.
Julg B; Dee L; Ananworanich J; Barouch DH; Bar K; Caskey M; Colby DJ; Dawson L; Dong KL; Dubé K; Eron J; Frater J; Gandhi RT; Geleziunas R; Goulder P; Hanna GJ; Jefferys R; Johnston R; Kuritzkes D; Li JZ; Likhitwonnawut U; van Lunzen J; Martinez-Picado J; Miller V; Montaner LJ; Nixon DF; Palm D; Pantaleo G; Peay H; Persaud D; Salzwedel J; Salzwedel K; Schacker T; Sheikh V; Søgaard OS; Spudich S; Stephenson K; Sugarman J; Taylor J; Tebas P; Tiemessen CT; Tressler R; Weiss CD; Zheng L; Robb ML; Michael NL; Mellors JW; Deeks SG; Walker BD
Lancet HIV; 2019 Apr; 6(4):e259-e268. PubMed ID: 30885693
[TBL] [Abstract][Full Text] [Related]
12. Acceptability, motivation and the prospect of cure for people living with HIV and their healthcare providers in HIV cure-focused treatment interruption studies.
Lau JSY; Smith MZ; Allan B; Martinez C; Power J; Lewin SR; McMahon JH
AIDS Res Ther; 2020 Nov; 17(1):65. PubMed ID: 33168019
[TBL] [Abstract][Full Text] [Related]
13. The Essential Need for Trust When Transmission Risk Cannot Be Eliminated in HIV-Remission Trials.
Rennie S; Henderson G; Phanuphak N; Kuczynski K; Colby D; Ormsby N; Kroon E; Hsu D; Likhitwonnawut U; Vasan S; Sacdalan C; Jupimai T; Butterworth O; Peay H
Ethics Hum Res; 2023; 45(4):2-15. PubMed ID: 37368521
[TBL] [Abstract][Full Text] [Related]
14. Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations.
Garner SA; Rennie S; Ananworanich J; Dube K; Margolis DM; Sugarman J; Tressler R; Gilbertson A; Dawson L
J Virus Erad; 2017 Apr; 3(2):82-84. PubMed ID: 28435691
[TBL] [Abstract][Full Text] [Related]
15. Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA.
Strongin Z; Sharaf R; VanBelzen DJ; Jacobson JM; Connick E; Volberding P; Skiest DJ; Gandhi RT; Kuritzkes DR; O'Doherty U; Li JZ
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593048
[TBL] [Abstract][Full Text] [Related]
16. Operationalizing Human Immunodeficiency Virus Cure-related Trials with Analytic Treatment Interruptions During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: A Collaborative Approach.
Peluso MJ; Dee L; Shao S; Taylor J; Campbell D; Collins S; Gandhi M; Johnston R; Deeks SG; Sauceda JA; Dubé K
Clin Infect Dis; 2021 May; 72(10):1843-1849. PubMed ID: 32841311
[TBL] [Abstract][Full Text] [Related]
17. Participant experiences using novel home-based blood collection device for viral load testing in HIV cure trials with analytical treatment interruptions.
Dubé K; Agarwal H; Carter WB; Dee L; Taylor J; Roebuck C; Peterson B; Patel H; Ndukwe S; Lynn KM; Lalley-Chareczko L; Hiserodt E; Kim S; Rosenbloom D; Evans BR; Anderson M; Hazuda DJ; Bateman K; Howell BJ; Azzoni L; Mounzer K; Tebas P; Montaner LJ
HIV Res Clin Pract; 2022 Aug; 23(1):76-90. PubMed ID: 35968737
[No Abstract] [Full Text] [Related]
18. Characterization of Physicians That Might Be Reluctant to Propose HIV Cure-Related Clinical Trials with Treatment Interruption to Their Patients? The ANRS-APSEC Study.
Protiere C; Fressard L; Mora M; Meyer L; Préau M; Suzan-Monti M; Lelièvre JD; Lambotte O; Spire B; The Apsec Study Group
Vaccines (Basel); 2020 Jun; 8(2):. PubMed ID: 32585921
[TBL] [Abstract][Full Text] [Related]
19. "We Need to Deploy Them Very Thoughtfully and Carefully": Perceptions of Analytical Treatment Interruptions in HIV Cure Research in the United States-A Qualitative Inquiry.
Dubé K; Evans D; Dee L; Sylla L; Taylor J; Skinner A; Weiner BJ; Greene SB; Rennie S; Tucker JD
AIDS Res Hum Retroviruses; 2018 Jan; 34(1):67-79. PubMed ID: 28562069
[TBL] [Abstract][Full Text] [Related]
20. Applying the Behavioural and Social Sciences Research (BSSR) Functional Framework to HIV Cure Research.
Dubé K; Auerbach JD; Stirratt MJ; Gaist P
J Int AIDS Soc; 2019 Oct; 22(10):e25404. PubMed ID: 31665568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
